Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3207-3215

  Zheng, Bei ^a   Georgakis, Georgios V ^a   Li, Yang ^a   Bharti, Alok ^a   McConkey, David ^a   Aggarwal, Bharat B ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFONYL) 2H TETRAZOLIUM; BORTEZOMIB; CASPASE; CD30 ANTIGEN; CD40 ANTIGEN; DEATH RECEPTOR 5; GEMCITABINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN P21; REGULATOR PROTEIN; TETRAZOLIUM; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REED STERNBERG CELL; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ANTIGENS, CD40; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BORONIC ACIDS; CARRIER PROTEINS; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; HODGKIN DISEASE; HUMANS; I-KAPPA B PROTEINS; MEMBRANE GLYCOPROTEINS; MULTIENZYME COMPLEXES; MUTATION; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442549643     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0494     Document Type: Article

References (37)

1. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Investig 2001;107:241-6.
2. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Investig 2001;107:135-42.
3. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
4. Younes A, Garg A, Aggarwal BB. Nuclear transcription factor-κ B in Hodgkin's disease. Leuk Lymphoma 2003;44:929-35.
5. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med 2000;191:207-12.
6. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-κ B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996;87:4340-7.
7. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Investig 1997;100:2961-9.
8. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I κ B α without inhibition of NF-κB activity and mutations in the I κ B α gene in Reed-Sternberg cells. Blood 1999;94:3129-34.
9. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumor suppressor role for IκBα. Oncogene 1999;18:3063-70.
10. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000;191:395-402.
11. Eliopoulos AG, Stack M, Dawson CW, et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 1997;14:2899-916.
12. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999;18:943-53.
13. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-97.
14. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003;4:192-201.
15. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003;8:307-15.
16. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
17. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
18. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
19. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
20. Aghajanian C, Soignet S, Dizon DS, et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
21. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003;29(Suppl 1):S33-9.
22. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines Leuk Lymphoma 1993;9:1-25.
23. Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998;103:270-5.
24. Younes A, Drach J, Katz R, et al. Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3. Ann Oncol 1994;5:265-8.
25. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-93.
26. Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997;15:3355-62.
27. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κ B and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-62.
28. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal BB, Younes A. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood 2001;98:2784-90.
29. Lee SY, Kandala G, Liou ML, Liou HC, Choi Y. CD30/TNF receptor-associated factor interaction: NF-κ B activation and binding specificity. Proc Natl Acad Sci USA 1996;93:9699-703.
30. Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 1995;25:2083-9.
31. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003;102:1019-27.
32. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999;14:135-43.
33. Kadin ME. Pathology of Hodgkin's disease. Curr Opin Oncol 1994;6:456-63.
34. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000;14:1276-83.
35. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003;171:88-95.
36. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9:1145-54.
37. Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-10.